Eli Lilly’s blockbuster obesity and diabetes drugs Zepbound and Mounjaro are no longer in shortage, according to the Food and Drug Administration.It’s a sign that pharmaceutical firm Lilly is making strides to improve the supply issues that have plagued the sector.

The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making custom-made versions.

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit cheaper copycat versions.